14-Hydroxy-dihydro-thebainon-4-methylether | 5140-32-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 14-Hydroxy-dihydro-thebainon-4-methylether
• 英文别名: 3,4-Dimethoxy-14-hydroxy-N-methyl-6-oxomorphinan；(1R,9R,10S)-10-hydroxy-3,4-dimethoxy-17-methyl-17-azatetracyclo[7.5.3.01,10.02,7]heptadeca-2(7),3,5-trien-13-one
• CAS: 5140-32-9
• 化学式: C₁₉H₂₅NO₄
• 分子量: 331.412
• InChiKey: VCBKOGTZQNFBOT-ATZDWAIDSA-N

物化性质

• 熔点：
  153-154 °C(Solv: methanol (67-56-1))
• 沸点：
  506.1±50.0 °C(Predicted)
• 密度：
  1.27±0.1 g/cm3(Predicted)
• 溶解度：
  溶于二氯甲烷

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  24
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.63
• 拓扑面积：
  59
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Process for improved oxycodone synthesis
  申请人：RHODES TECHNOLOGIES

  公开号：US10844072B2

  公开（公告）日：2020-11-24

  Processes for preparing oxycodone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxycodeinone salt in the presence of trifluoroacetic acid and/or a glycol.

  提供了制备羟考酮的工艺。所述工艺包括一个步骤，即在三氟乙酸和/或乙二醇存在下氢化 14-羟基可待因酮盐。
• PROCESS FOR IMPROVED OXYCODONE SYNTHESIS
  申请人：RHODES TECHNOLOGIES

  公开号：US20200199134A1

  公开（公告）日：2020-06-25

  Processes for preparing oxycodone are provided. Said processes encompass a step which is a hydrogenation of an 14-hydroxycodeinone salt in the presence of trifluoroacetic acid and/or a glycol.
• NOVEL OPIOID COMPOUNDS AND USES THEREOF
  申请人：RHODES TECHNOLOGIES

  公开号：US20210061815A1

  公开（公告）日：2021-03-04

  This invention relates to novel opioid derivatives of Formula I: or a pharmaceutically acceptable salt or solvate thereof, wherein R 1 , R 3 , R 4 and Z are as defined herein in the disclosure. The invention also relates to the use of such compounds for the treatment or prevention of, for example, pain.
• US9932348B2
  申请人：——

  公开号：US9932348B2

  公开（公告）日：2018-04-03
• [EN] PRODRUGS AND METHODS OF MAKING AND USING THE SAME<br/>[FR] PROMÉDICAMENTS ET PROCÉDÉS POUR LES FABRIQUER ET LES UTILISER
  申请人：NEUROGESX INC

  公开号：WO2008070149A2

  公开（公告）日：2008-06-12

  [EN] Prodrugs of parent drugs and methods of making and using the same are described. The prodrugs comprise an amine-containing parent drug moiety and a prodrug moiety, such as methoxyphosphonic acid or ethoxyphosphonic acid. The prodrugs may be employed in therapy for the treatment of various indications, such as pain, and in methods of decreasing the abuse potential of abuse-prone drugs and/or delaying the onset of parent drug activity and/or prolonging parent drug activity as compared to administration of a parent drug.
  [FR] L'invention concerne des promédicaments de médicaments parents et des procédés pour les fabriquer et les utiliser. Les promédicaments comprennent un groupe caractéristique de médicaments parents contenant une amine et un groupe caractéristique de promédicaments, tels que l'acide méthoxyphosphonique ou l'acide éthoxyphosphonique. Les médicaments peuvent être employés pour le traitement de diverses indications, telles que la douleur, et dans des procédés de diminution du potentiel d'abus de médicaments susceptibles d'abus et/ou retarder le début de l'activité du médicament parent et/ou prolonger l'activité du médicament parent si l'on compare à l'administration d'un médicament parent.